drugset / Trial / NCT06844383
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
Phase 2
Recruiting
126 enrolled
Prostate Cancer Clinical Trials Consortium
Dana-Farber Cancer Institute · collabMemorial Sloan Kettering Cancer Center · collabPfizer · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have homologous recombination repair (HRR) mutations and have previously received abiraterone acetate.
Timeline
- Start
- 2026-05-05
- Primary completion
- 2029-03
- Completion
- 2030-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Enzalutamide | Other / unclassified | 160 mg | Oral |
| Comparator | Talazoparib | Small molecule | 0.5 mg | Oral |
| Comparator | Talazoparib | Small molecule | 1 mg | Oral |